💉FDA's Regulatory Review Period Determination for AVEIR VR System
Determination of Regulatory Review Period for Purposes of Patent Extension; [AVEIR VR LEADLESS SYSTEM]
Summary
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for AVEIR VR Leadless System and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.
Agencies
- Health and Human Services Department
- Food and Drug Administration
Business Impact
$$$ - High
The FDA's determination of the regulatory review period for the AVEIR VR Leadless System and potential patent extension has significant implications for patent owners and medical device manufacturers, impacting financial planning and market strategies. Compliance may be required for submitting comments and petitions regarding patent extensions.